US05465V1089 - Common Stock
AYALA PHARMACEUTICALS INC
NASDAQ:AYLA (1/18/2023, 7:00:01 PM)
0.5036
+0.03 (+5.84%)
Ayala Pharmaceuticals, Inc. operates as a clinical-stage oncology company. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-05-08. The firm's portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors (GSIs). AL101 and AL102 are designed to address the underlying key drivers of tumor growth. The firm is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC), for patients bearing Notch-activating mutations. The firm also developing AL102 for the treatment of other rare indications including T-ALL, an aggressive, rare form of T-cell specific leukemia. The firm is also conducting its ongoing Phase II ACCURACY trial for the treatment of R/M ACC in subjects with progressive disease and Notch-activating mutations.
AYALA PHARMACEUTICALS INC
1313 N. Market Street, Suite 5100
Wilmington DELAWARE 7670104
P: 18574440553.0
CEO: Roni Mamluk
Employees: 35
Website: https://www.ayalapharma.com/
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company...
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders...
Here you can normally see the latest stock twits on AYLA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: